| Oxybutynin and Omega-3 for OAB (Overactive Bladder) (NCT02070042) | TriHealth Inc. | 2014-02-01 |
| Time of Effect Onset in Treating Overactive Bladder or Non Obstructive Urinary Retention by Sacral Neuromodulation (NCT02040519) | Maastricht University Medical Center | 2014-01-01 |
| This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder (NCT01972841) | Astellas Pharma Europe B.V. | 2013-11-05 |
| Gene Expression in the Overactive Bladder in Children (NCT02086058) | University of Aarhus | 2013-11-01 |
| Electrical Nerve Stimulation for Overactive Bladder a Comparison of Treatments (NCT01940367) | Walter Reed National Military Medical Center | 2013-10-01 |
| Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment (NCT01955408) | Meir Medical Center | 2013-09-30 |
| Cardiovascular Morbidity During Treatment of Overactive Bladder With B3 Agonists (NCT02622555) | Karolinska Institutet | 2013-08-01 |
| OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER (NCT01050114) | Christopher Patrick Smith | 2013-08-01 |
| The Effect of Urox™ in the Treatment of Overactive Bladder and Urinary Incontinence (NCT02396160) | The University of Queensland | 2013-08-01 |
| Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder (NCT01868516) | Targacept Inc. | 2013-05-01 |
| Utilization of the BIOWAVE Device to Treat Overactive Bladder (NCT01848366) | Kenneth Peters, MD | 2013-05-01 |
| Bladder Thermal Distention for Patients With Refractory Overactive Bladder (NCT01842685) | Assaf-Harofeh Medical Center | 2013-04-01 |
| Pilot Study of Mirabegron in Pediatric Patients With Overactive Bladder (NCT02468830) | CHU de Quebec-Universite Laval | 2013-04-01 |
| Add-on Mirabegron in Pediatric Patients With Refractory Overactive Bladder (NCT02476175) | CHU de Quebec-Universite Laval | 2013-04-01 |
| A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence (NCT01767519) | Allergan | 2013-03-01 |
| Flexibly adding-on Second Antimuscarinic Agent to the First Antimuscarinics for Refractory Overactive Bladder Syndrome (NCT01824420) | Buddhist Tzu Chi General Hospital | 2013-03-01 |
| A Single-Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Adults With Hepatic Insufficiency (MK-4618-013) (NCT01737684) | Merck Sharp & Dohme LLC | 2013-01-15 |
| Clinical and Biochemical Evidence of Neurogenic Inflammation in Women With Urinary Urgency (NCT01933074) | University of Pennsylvania | 2013-01-01 |
| Transcutaneous Tibial Nerve Stimulation of Patients With Overactive Bladder (OAB) Syndrome (NCT02790307) | University College, London | 2013-01-01 |
| Use of Percutaneous Tibial Nerve Stimulation With Solifenacin or Placebo to Treat Refractory Overactive Bladder (NCT01764893) | Bay State Clinical Trials, Inc. | 2013-01-01 |
| Interventional Clinical Trial in Patients in Overactive Bladder With Nocturia in Women (NCT01729819) | Ferring Pharmaceuticals | 2013-01-01 |
| Phase 1 Study With OAB Assessing the Safety and Activity of hMaxi-K Gene Transfer (NCT01870037) | Urovant Sciences GmbH | 2013-01-01 |
| Post Marketing Study to Evaluate the Efficacy and Safety of Solifenacin in Patients With OAB (Overactive Bladder) After TURP (Trans-urethral Resection of Prostate) or PVP (Photoselective Vaporization of Prostate) (NCT01747577) | Astellas Pharma Korea, Inc. | 2012-12-04 |
| Specified Drug Use-results Survey of Betanis Tablets (NCT01898624) | Astellas Pharma Inc | 2012-12-04 |
| Specified Drug Use-results Survey of Betanis Tablets for Patients With Coexisting Cardiovascular Disease (NCT02570035) | Astellas Pharma Inc | 2012-12-01 |
| A Study to Evaluate the Effect of Mirabegron + Solifenacin in Overactive Bladder Patients (NCT01745094) | Astellas Pharma Inc | 2012-10-01 |
| Urinary Biomarkers For Objective Measurement Of InterStim® Response In Over Active Bladder (OAB) Patients. (NCT01739946) | Michael Chancellor, MD | 2012-10-01 |
| Long-Term Specified Drug Use-results Survey of Betanis Tablets (NCT01901120) | Astellas Pharma Inc | 2012-10-01 |
| A Single Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Participants With Renal Insufficiency (MK-4618-014) (NCT01628042) | Merck Sharp & Dohme LLC | 2012-07-16 |
| Bacterial Genomic Sequencing in Overactive Bladder (NCT01642277) | Loyola University | 2012-07-01 |
| Microbiomes of Pelvic Pain (NCT01738464) | Northwestern University | 2012-06-01 |
| Trial of Percutaneous Tibial Nerve Stimulation (PTNS) Versus PTNS and Fesoterodine Fumarate (NCT01605617) | Mayo Clinic | 2012-06-01 |
| Premarin Versus Toviaz for Treatment of Overactive Bladder (NCT01613170) | The Cleveland Clinic | 2012-04-01 |
| Drug Use-Results Survey of Betanis Tablets in Japan (NCT01919047) | Astellas Pharma Inc | 2012-04-01 |
| Single Dose Study to Measure Blood Levels and Safety of a Drug for Children With Overactive Bladder (NCT01539707) | Astellas Pharma Inc | 2012-03-13 |
| An Exploratory Study to Investigate Bladder Contractions in the Storage Phase and Related Bladder Sensations in Healthy Females and Females With Overactive Bladder (OAB) Using High Resolution and Conventional Urodynamics (NCT01540786) | Astellas Pharma Europe Ltd. | 2012-03-01 |
| A Study of the Pharmacokinetics and Pharmacodynamics of Vibegron (MK-4618) in Women With Overactive Bladder (MK-4618-004) (NCT01500382) | Merck Sharp & Dohme LLC | 2012-02-27 |
| Painless Laser Therapy for Overactive Bladder (NCT01569061) | Zipper Urogynecology Associates | 2012-02-01 |
| Therapy of the Overactive Bladder Syndrome (NCT01314781) | Cantonal Hospital, Frauenfeld | 2012-01-01 |
| Urgent-SQ in Treatment of Overactive Bladder Syndrome: 9-yr Follow up (NCT01644409) | Radboud University Medical Center | 2012-01-01 |
| Clinical and Urodynamic Predictors for Sacral Neuromodulation Outcomes in Overactive Bladder (NCT03156088) | Assiut University | 2012-01-01 |
| Supraspinal Control of Lower Urinary Tract Function in Healthy Controls and Patients With Bladder Dysfunction (NCT01768910) | University of Zurich | 2011-12-01 |
| Effectiveness and Safety Study of Solifenacin Succinate and Solifenacin Succinate + Estrogen to Treat OAB in Postmenopausal Women (NCT01833663) | Peking Union Medical College Hospital | 2011-10-01 |
| Evaluation of Autonomic System Before and After Anticholinergic Treatment in Women With Overactive Bladder (NCT01409512) | Rambam Health Care Campus | 2011-09-01 |
| Observational Study to Estimate the Dry Mouth in OAB Patients With Solifenacin (NCT01437670) | Asan Medical Center | 2011-09-01 |
| Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder (NCT01423838) | Adana Numune Training and Research Hospital | 2011-09-01 |
| A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder. (NCT01458197) | Kwang Dong Pharmaceutical co., ltd. | 2011-09-01 |
| Safety and Effectiveness of a Non-invasive Neuromodulation Device on Urgency Urinary Incontinence in Overactive Bladder (NCT01369485) | Ethicon Endo-Surgery | 2011-06-01 |
| A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of Fesoterodine (NCT01302067) | Pfizer | 2011-05-01 |
| Validation of Instruments for Pragmatic Clinical Trials for Overactive Bladder (NCT01925456) | University of Pennsylvania | 2011-05-01 |
| Web-based Methodology Trial to Evaluate the Efficacy and Safety of Tolterodine ER in Subjects With Overactive Bladder (NCT01302938) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2011-03-01 |
| Interventions to Enhance Medication Persistence and Compliance in Patients With Overactive Bladder (NCT01515722) | Samsung Medical Center | 2010-12-01 |
| Study of AOBO-001 for Overactive Bladder With Urge Urinary Incontinence and Frequency (NCT01294982) | American Oriental Bioengineering, Inc. | 2010-12-01 |
| The Efficacy of Solifenacin With or Without Tamsulosin in Adult Women With Overactive Bladder (OAB) (NCT01533597) | Soonchunhyang University Hospital | 2010-12-01 |
| Comparison of Efficacy and Safety Between Imidafenacin and Fesoterodine in Patients With Overactive Bladder (NCT01578304) | LG Life Sciences | 2010-12-01 |
| Physical Therapy for Overactive Bladder (NCT01758848) | National Taiwan University Hospital | 2010-09-01 |
| Effects of Antimuscarinic Drugs on Overactive Bladder (OAB) Symptoms After Insertion of Ureteral Stents (NCT01210859) | Meir Medical Center | 2010-09-01 |
| Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) Trial (NCT01178827) | Allergan | 2010-08-01 |
| Comparative Urine Proteomic Studies of Overactive Bladder in Humans (NCT01367886) | Washington University School of Medicine | 2010-08-01 |
| Combined Behavioral and Drug Treatment of Overactive Bladder in Men (NCT01175382) | University of Alabama at Birmingham | 2010-07-01 |
| Post Marketing Survey of Vesicare in Japan (NCT01489709) | Astellas Pharma Inc | 2010-06-01 |
| Study to Gather Information About the Actual Use of an Adhesive Patch Placed on the Skin to Deliver Oxytrol Through the Skin Into the Bloodstream. (NCT04534491) | Bayer | 2010-05-25 |
| Effects and Safety of Liposome Encapsulated Botulinum Toxin A for Overactive Bladder Syndrome (NCT01167257) | Buddhist Tzu Chi General Hospital | 2010-05-01 |
| Clinical Trial to Study a Non-invasive Neurostimulation Device on Urgency (Urinary) Incontinence Overactive Bladder (OAB) (NCT01125722) | Ethicon Endo-Surgery | 2010-04-01 |
| Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily (NCT01089751) | Allergan | 2010-03-01 |
| Anticholinergic vs. Botox Comparison Study (NCT01166438) | NICHD Pelvic Floor Disorders Network | 2010-03-01 |
| Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence (NCT00915525) | Allergan | 2010-02-01 |
| Urinary Nerve Growth Factor (NGF), Prostaglandin E2 (PGE2)and Adenosine Triphosphate (ATP): Potential Biomarkers in Overactive Bladder Patients (NCT01499069) | Samsung Medical Center | 2010-02-01 |
| Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder. (NCT01093534) | Astellas Pharma Inc | 2010-01-19 |
| Propiverine Hydrochloride Extended-Release Capsule for Overactive Bladder (NCT01512004) | Lee's Pharmaceutical Limited | 2010-01-01 |
| Grouptraining for Overactive Bladder in Adults (NCT01187082) | University of Aarhus | 2009-12-01 |
| Toviaz Post Marketing Surveillance Study (NCT00879398) | Pfizer | 2009-11-01 |
| A Clinical Study for Magnetic Stimulation of the Posterior Tibial Nerve in Overactive Bladder (NCT01214265) | EMKinetics, Inc | 2009-10-01 |
| Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence (NCT00910845) | Allergan | 2009-09-01 |
| A Study to Evaluate Response of Overactive Bladder Symptom Score (OABSS) to Treatment (NCT01122563) | Astellas Pharma Inc | 2009-09-01 |
| Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen (NCT01003249) | Wake Forest University Health Sciences | 2009-09-01 |
| Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence (NCT00910520) | Allergan | 2009-09-01 |
| A Study Of Efficacy And Safety Of Fesoterodine In Vulnerable Elderly Subjects With Overactive Bladder (NCT00928070) | Pfizer | 2009-09-01 |
| Reproducibility Study of OABSS and Its Response to Treatment (NCT02667470) | Astellas Pharma Inc | 2009-09-01 |
| Reproducibility Study of Overactive Bladder Symptom Score [OABSS] (NCT01122550) | Astellas Pharma Inc | 2009-09-01 |
| A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary Urgency (NCT00911937) | Pfizer | 2009-08-01 |
| Preoperative Use of Darifenacin (Enablex) to Alleviate Postoperative Ureteral Stent Pain (NCT01189071) | University of Missouri-Columbia | 2009-08-01 |
| Evaluation of Adherence to Solifenacin Treatment in Overactive Bladder Patients (NCT00985387) | Astellas Pharma Inc | 2009-08-01 |
| This Is An Open-Label Study To Evaluate Fesoterodine Plus "Your Way" Patient Support Plan In Patients With Symptoms Of Overactive Bladder (NCT00943735) | Pfizer | 2009-07-01 |
| Trospium Chloride XR in Obese Female Patients With Overactive Bladder (NCT00932022) | Allergan | 2009-07-01 |
| Comparison of Motor and Sensory Response With Interstim Stimulation (NCT00943904) | University of California, Irvine | 2009-07-01 |
| Botox for the Treatment of Overactive Bladder Secondary to Benign Prostatic Obstruction (NCT01220726) | Weill Medical College of Cornell University | 2009-06-01 |
| Pain-perception During Outpatient cystoscopy-a Prospective Controlled Study (NCT01663181) | Medical University of Vienna | 2009-05-01 |
| Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) Trial (NCT00863551) | Allergan | 2009-04-01 |
| Solifenacin Flexible Dosing Study in Frequent Micturition Patients With and Without Urgency (NCT00979472) | Asan Medical Center | 2009-04-01 |
| Study of ONO-8539 in Patients With Overactive Bladder (NCT00876421) | Ono Pharmaceutical Co., Ltd. | 2009-04-01 |
| Study Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years (NCT00857896) | Pfizer | 2009-03-01 |
| A Study to Evaluate Add on Effect of Solifenacin in Men With Overactive Bladder Symptoms After Tamsulosin Monotherapy for 4 Weeks (NCT00884104) | KYU-SUNG LEE | 2009-03-01 |
| Assessment of Patient-reported Goal Attainment in the Treatment of Female Overactive Bladder (NCT00836381) | Samsung Medical Center | 2009-02-01 |
| Bringing Simple Urge Incontinence Diagnosis & Treatment to Providers (BRIDGES) (NCT00862745) | University of California, San Francisco | 2009-01-01 |
| A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis (NCT00876447) | Allergan | 2009-01-01 |
| Reproducibility Study of Over Active Bladder Symptom Score [OABSS] (NCT00901251) | Astellas Pharma Inc | 2009-01-01 |
| Hypnotherapy for Treatment of Overactive Bladder (NCT00793611) | University of New Mexico | 2008-11-01 |
| Solifenacin Succinate Versus Placebo in Inner City Women Ages 20-45 With Overactive Bladder (NCT00773552) | Stamford Hospital | 2008-11-01 |
| Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Benign Prostatic Hyperplasia (NCT00771394) | Astellas Pharma Inc | 2008-10-01 |